AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome

Aug 29, 2023Alzheimer's & dementia : the journal of the Alzheimer's Association

Brain protein patterns and Alzheimer's symptoms in people with Down syndrome

AI simplified

Alzheimers & Treatments on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Overall, 69.8% of adults with Down syndrome (DS) were classified as amyloid (A)-/tau (T)-/neurodegeneration (N)-.

11.1% of participants were classified as A+/T-/(N)-, indicating the presence of amyloid without tau pathology.
5.6% were categorized as A+/T+/(N)-, suggesting both amyloid and tau presence without neurodegeneration.
9.3% were identified as A+/T+/(N)+, reflecting amyloid and tau pathology alongside neurodegeneration.
Participants with stable cognition predominantly fell into the A-T-(N)- and A+T-(N)- groups.
Tau PET (T+) was most closely associated with memory impairment and clinical Alzheimer's disease status.

AI simplified

INTRODUCTION: Down syndrome (DS) is a genetic cause of early-onset Alzheimer's disease (AD). The National Institute on Aging-Alzheimer's Association AT(N) Research Framework is a staging model for AD biomarkers but has not been assessed in DS.

METHOD: Data are from the Alzheimer's Biomarker Consortium-Down Syndrome. Positron emission tomography (PET) amyloid beta (Aβ; 15 mCi of [C]Pittsburgh compound B) and tau (10 mCi of [F]AV-1451) were used to classify amyloid (A) -/+ and tau (T) +/-. Hippocampal volume classified neurodegeneration (N) -/+. The modified Cued Recall Test assessed episodic memory. 11 18

RESULTS: Analyses included 162 adults with DS (aged M = 38.84 years, standard deviation = 8.41). Overall, 69.8% of participants were classified as A-/T-/(N)-, 11.1% were A+/T-/(N)-, 5.6% were A+/T+/(N)-, and 9.3% were A+/T+/(N)+. Participants deemed cognitively stable were most likely to be A-T-(N)- and A+T-(N)-. Tau PET (T+) most closely aligning with memory impairment and AD clinical status.

DISCUSSION: Findings add to understanding of AT(N) biomarker profiles in DS.

HIGHLIGHTS: Overall, 69.8% of adults with Down syndrome (DS) aged 25 to 61 years were classified as amyloid (A)-/tau (T)-/neurodegeneration (N)-, 11.1% were A+/T-/(N)-, 5.6% were A+/T+/(N)-, and 9.3% were A+/T+/(N)+. The AT(N) profiles were associated with clinical Alzheimer's disease (AD) status and with memory performance, with the presence of T+ aligned with AD clinical symptomology. Findings inform models for predicting the transition to the prodromal stage of AD in DS.

Full Text

Full text is available at the source.

View full text ↗

AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief